“…Despite the current declines in prostate cancer mortality in the United States, African American (AA) men continue to experience a 60% higher incidence of prostate cancer and are twice as likely to die from prostate cancer in comparison to Whites (American Cancer Society, 2016b). There has been a consistent strategy employed to address prostate cancer disparities, notwithstanding an increased effort to provide prostate cancer screening as a clinical standard (Green, Davis, Rivers, Buchanan, & Rivers, 2014). However, there is ongoing concern that the prostate-specific antigen (PSA) test contributes to an increase in false positives/false negatives and overdiagnosis that can lead to overtreatment, which exposes men to adverse treatment-related side effects such as incontinence and erectile dysfunction (National Cancer Institute [NCI], 2017b).…”